Merck (MRK) Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street wavers as Federal Reserve holds key rate steady, pending more data
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
| Merck & Co. (NYSE: MRK) | Delayed: 140.42 -1.4 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $141.82 | 52 Week High | $65.46 | |||
| Open | $140.00 | 52 Week Low | $47.97 | |||
| Day High | $142.40 | P/E | 95.52 | |||
| Day Low | $139.21 | EPS | $1.47 | |||
| Volume | 3,766,404 | |||||
